Portfolio

Our Innovative Programs

We are the only company developing an integrated platform to change the treatment landscape in both autologous and allogeneic transplant, and provide access to a one-time curative treatment option for more patients with autoimmune diseases, hematologic malignancies, and genetic diseases. We are developing a portfolio of biologics, including antibody drug conjugates, small molecules, and a cell therapy. Our product candidates can each be used individually or in combination with each other to create tailored treatment regimens for individual patients. 

Autoimmune Disease

CompoundPreclinicalIND-EnablingPhase IPhase IIPhase IIIApproved

CD45-ADC

C300

MGTA-145

Genetic Diseases

CompoundPreclinicalIND-EnablingPhase IPhase IIPhase IIIApproved

CD117-ADC

MGTA-145

MGTA-456

G100

E478

Blood Cancers

CompoundPreclinicalIND-EnablingPhase IPhase IIPhase IIIApproved

CD117-ADC

C300

MGTA-145

MGTA-456

G100